Elevated serum REG1B and REG3G correlate with atherosclerosis diagnosis and disease severity, including a signal for distinguishing early non-obstructive disease. The study reports both biomarkers are higher in patients with diagnosed atherosclerosis and show stratification by severity metrics. REG1B was specifically highlighted as distinguishing early non-obstructive disease, suggesting potential utility for earlier risk detection rather than only advanced pathology tracking. For biotech, the findings add to the growing menu of circulating biomarkers aimed at refining risk stratification beyond traditional lipid measures. As with all biomarker studies, translation will depend on assay standardization and validation in independent cohorts with prospective outcomes. The immediate relevance is pipeline: these biomarkers could serve as companion diagnostics candidates for studies evaluating anti-inflammatory or lipid-modifying interventions in early atherosclerosis.
Get the Daily Brief